Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.SkyePharma names new CEO
In accordance with the company’s management succession plan Frank Condella will be succeeded by Ken Cunningham, currently COO. Mr Condella will continue on the board as a non-executive
In accordance with the company’s management succession plan Frank Condella will be succeeded by Ken Cunningham, currently COO. Mr Condella will continue on the board as a non-executive
In this 120-patient, multi-center, randomized, controlled study 90 patients will receive the VESTAsync nano-porous hydroxyapatite (HAp) coated drug-eluting stent, while 30 patients will receive the company’s VESTAcor stent,
The study was discontinued at the recommendation of the steering committee based on its review and evaluation of scientific data from recent carotid intima-media thickness (cIMT) studies. This
The Sirflox study, which will take place at 25-35 sites in Australia, the US, EU and New Zealand, is the largest of its kind. It will involve 318
In the preclinical study of Plexxikon’s polycystic kidney disease (PKD) drug candidate, doses of the drug candidate were administered orally daily for 14 days. A marked reduction in
This analysis, designed and completed following the closure of the five-year Treating to New Targets (TNT) study. The TNT study was an investigator led trial coordinated by independent
The company is planning to submit an investigational new drug (IND) application to the FDA later 2008 to commence a Phase I clinical trial for its cancer stem
This open label, dose escalation, Phase I study determines the maximum tolerated dose of LE-DT in patients with metastatic solid cancer who have failed conventional therapy. Up to
Since October 2008, BARC has performed peripheral blood mononuclear cell (PBMC)-isolation services for the HVTN HIV vaccine trials at various locations in South Africa. Under the new agreement,
The patent covers compositions of matter and uses of Aeriva, a fusion protein that combines secretory leukocyte protease inhibitor (SLPI) and recombinant alpha 1-antitrypsin (rAAT). The Aeriva protein,